Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma.

导出 LinkOut

翻译打印收藏纠错

作者： Walid,Shalata ^[1] ; Rachel,Steckbeck ^[2] ; Ilya,Polishchuk ^[3] ; Ahron Yehonatan,Cohen ^[1] ; Keren,Rouvinov ^[1] ; Margarita,Tokar ^[1] ; Ashraf,Abu Jama ^[1] ; Omar,Abu Saleh ^[3] ; Kim,Sheva ^[4] ; Alexander,Yakobson ^[1]

作者单位： The Legacy Heritage Center & Dr. Larry Norton Institute, Soroka Medical Center and Ben Gurion University, Beer Sheva, Israel. ^[1] Medical School for International Health, Ben Gurion University of the Negev, Beer Sheva, Israel. ^[2] Internal Medicine Ward, Soroka Medical Center & Ben-Gurion University, Beer-Sheva, Israel. ^[3] Department of Dermatology and Venereology, Emek Medical Centre, Afula, Israel. ^[4]

关键词 BRAF mutation (V600E)dabrafenib hyperbilirubinemia metastatic melanoma safety trametinib

DOI 10.3389/fonc.2023.1102330

PMID 36865793

发布时间 2023-03-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

Frontiers in oncology

2023年13卷

1102330页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

检索历史清除